Claims for Patent: 11,364,233

Summary for Patent: 11,364,233

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	17/468,149
Patent Claims:	1. A method of increasing a plasma level of dextromethorphan, comprising co-administering a bupropion and a dextromethorphan to a human being who is a non-poor metabolizer of dextromethorphan, wherein the human being receives about 70 mg to about 150 mg of the bupropion and about 30 mg to about 60 mg of the dextromethorphan once a day for three consecutive days followed by twice a day for at least 5 consecutive days, and wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is at least about 700 nghr/mL. 2. The method of claim 1, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 20 times to about 1,000 times the AUC.sub.0-12 that would result from administering 60 mg of dextromethorphan hydrobromide without bupropion for eight consecutive days. 3. The method of claim 1, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 20 times to about 60 times the AUC.sub.0-12 that would result from administering 60 mg of dextromethorphan hydrobromide without bupropion for eight consecutive days. 4. The method of claim 1, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 30 times the AUC.sub.0-12 that would result from administering 60 mg of dextromethorphan hydrobromide without bupropion for eight consecutive days. 5. The method of claim 1, wherein the bupropion and the dextromethorphan are co-administered to the human being for at least 30 consecutive days. 6. The method of claim 1, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression. 7. The method of claim 1, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of nicotine addiction. 8. The method of claim 1, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of agitation associated with Alzheimer's disease. 9. The method of claim 1, wherein about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base or another salt form of bupropion, is co-administered with about 44 mg to about 46 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base or another salt form of dextromethorphan, to the human being once a day for 3 consecutive days followed by twice a day for at least 5 consecutive days. 10. The method of claim 1, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 700 nghr/mL to about 1686 nghr/mL. 11. The method of claim 10, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 20 times to about 1,000 times the AUC.sub.0-12 that would result from administering 60 mg of dextromethorphan hydrobromide without bupropion for eight consecutive days. 12. The method of claim 10, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 20 times to about 60 times the AUC.sub.0-12 that would result from administering 60 mg of dextromethorphan hydrobromide without bupropion for eight consecutive days. 13. The method of claim 10, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 30 times the AUC.sub.0-12 that would result from administering 60 mg of dextromethorphan hydrobromide without bupropion for eight consecutive days. 14. The method of claim 10, wherein the bupropion and the dextromethorphan are co-administered for at least 30 consecutive days. 15. The method of claim 10, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression. 16. The method of claim 10, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of nicotine addiction. 17. The method of claim 10, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of agitation associated with Alzheimer's disease. 18. The method of claim 10, wherein about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base or another salt form of bupropion, is co-administered with about 44 mg to about 46 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base or another salt form of dextromethorphan, to the human being once a day for 3 consecutive days followed by twice a day for at least 5 consecutive days. 19. The method of claim 1, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 750 nghr/mL. 20. The method of claim 19, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 20 times to about 1,000 times the AUC.sub.0-12 that would result from administering 60 mg of dextromethorphan hydrobromide without bupropion for eight consecutive days. 21. The method of claim 19, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 20 times to about 60 times the AUC.sub.0-12 that would result from administering 60 mg of dextromethorphan hydrobromide without bupropion for eight consecutive days. 22. The method of claim 19, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 30 times the AUC.sub.0-12 that would result from administering 60 mg of dextromethorphan hydrobromide without bupropion for eight consecutive days. 23. The method of claim 19, wherein the bupropion and the dextromethorphan are co-administered for at least 30 consecutive days. 24. The method of claim 19, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression. 25. The method of claim 19, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of nicotine addiction. 26. The method of claim 19, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of agitation associated with Alzheimer's disease. 27. The method of claim 19, wherein about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base or another salt form of bupropion, is co-administered with about 44 mg to about 46 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base or another salt form of dextromethorphan, to the human being once a day for 3 consecutive days followed by twice a day for at least 5 consecutive days.